Figure 3. Side effects within 7 days after vaccine or placebo was given*
How has this study helped patients and researchers?
This study helped researchers in 3 ways. It showed A summary of all the ways this study helped patients
that the vaccine was not able to reduce COPD and researchers may be found in the clinical results
exacerbations. It showed that the vaccine could summary.
stimulate a strong antibody response in those who
received it. It also confirmed that the rate of bacterial
(Haemophilus influenzae and Moraxella catarrhalis)
infection in this group of patients was what the
researchers had assumed it would be.
Are there plans for further studies?
No other studies were planned or ongoing to evaluate Medicines Agency and/or the United States National
the effectiveness of the study vaccine at the time this Institutes of Health. Links to this study are provided
summary was prepared. The results of any future at the end of the document.
studies will be available on the websites of European
Where can I find more information about this study?
The detailed title for this research study is:
A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety,
reactogenicity and immunogenicity of the GSK Biologicalsâ€™ investigational vaccine GSK3277511A when
administered intramuscularly according to a 0, 2 month schedule in COPD patients aged 40 to 80 years with a
previous history of acute exacerbation (AECOPD).
Clinical studies have unique study numbers. Below are the unique study numbers associated with this study.
.